Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18463779 | 0.87 | AR (0.35) | BACE1CYP1A2CYP2A6KDM4EPDE10A | |
| SCHEMBL10220179 | 0.85 | BACE1 (0.53) | BACE1CYP1A2CYP2A6CYP3A4CYP2C9 | |
| SCHEMBL5833184 | 0.79 | BACE1 (0.55) | BACE1CYP1A2CYP2A6CYP3A4CYP2C9 | |
| SCHEMBL12473918 | 0.79 | BACE1 (0.47) | BACE1CYP1A2CYP2A6CYP3A4CYP2C9 | |
| SCHEMBL18463931 | 0.79 | HTR3A (0.43) | BACE1CYP2A6PDE3BPDE3AKDM4E | |
| SCHEMBL18463859 | 0.76 | KDM4E (0.40) | BACE1CYP3A4CYP2C9CYP2C19KDM4E | |
| SCHEMBL18463935 | 0.76 | KDM4E (0.40) | BACE1CYP3A4CYP2C9CYP2C19KDM4E | |
| SCHEMBL18464484 | 0.73 | CYP1A2 (0.48) | BACE1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30976616 | 0.71 | BACE1 (0.50) | BACE1CYP1A2CYP2A6PDE3BPDE3A | |
| SCHEMBL384813 | 0.71 | CYP1A2 (0.63) | BACE1CYP1A2CYP2A6KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-28 | — | — | US | disclosed |
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-10-03 | — | — | US | disclosed |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-07-16 | — | — | US | disclosed |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300480-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | BACE1 1738/4885CYP1A2 4140/4885CYP2A6 3806/4885 |
| US-10633338-B2 | Binding Function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | BACE1 1738/4885CYP1A2 4140/4885CYP2A6 3806/4885 |
| US-10351527-B2 | Binding function 3 (BF3) site compounds as therapeutics and methods for their use | KLK3, SHBG, ACP3 | BACE1 1738/4885CYP1A2 4140/4885CYP2A6 3806/4885 |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | BACE1 1738/4885CYP1A2 4140/4885CYP2A6 3806/4885 |
| US-20170029372-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | BACE1 1738/4885CYP1A2 4140/4885CYP2A6 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.